Growth hormone responsiveness: Peak stimulated growth hormone levels and other variables in idiopathic short stature (ISS): Data from the national cooperative growth study

Pediatric Endocrinology Reviews

Volumn 6, Issue 1, 2008, Pages 5-8

  Moore, Wayne V ^a   Dana, Ken ^b   Frane, James ^c   Lippe, Barbara ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b GENENTECH INC   (United States)

^c NONE

Author keywords

Growth response; Idiopathic short stature (ISS); Peak growth hormone (GH)

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATREM;

AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY MASS; BONE AGE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPENDENT VARIABLE; DOSE TIME EFFECT RELATION; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONE RESISTANCE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE REGRESSION; PREDICTOR VARIABLE; PROVOCATION TEST; SEX DIFFERENCE; SHORT STATURE;

BODY HEIGHT; CHILD; CHILD DEVELOPMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; POPULATION SURVEILLANCE; RECOMBINANT PROTEINS; UNITED STATES;

EID: 53849103954     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Laron Z. Laron Syndrome (Primary growth hormone resistance or Insensitivity): The Personal Experience 1958-2003. J Clin Endocrinol Metab 2004;89:1031-1044
2. Chernausek SD, Backeljauw F, Frane J, Kuntze J, Underwood. Long-term treatment with recombinant insulin-like growth factor (IGF-I) in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;92:902-910
3. Savage MO, Attie KM, David A, Metherell LA, Clark AJL, Gamacho-Hubner C. Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nature Clinical Practice 2006;2:395-407
4. Martinelli, CE, Milani SS, Previato JK, Figueira, M, Montenegro APR, Miraki-Moud F, Betancourth S, Moreira AC, Savage MO, Camacho-Hubner C. Final height in patients with idiopathic short stature and high growth hormone responses to stimulation tests. Hormone Res 2007;76:224-230
5. Camacho-Hubner C, Rose S, Preece MA, Sleevi M, Storr HL, Miraki-Moud F, Minuto F, Frystyk J, Rogol AG, Sommer A, Savage MO. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/ rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endrocrinol Metab 2006;91:1246-1253
6. Bright GM, Julius JR, Lima J, Blethen SL. Growth hormone stimulation test results as predictors of recombinant human growth hormone treatment outcomes: Preliminary analysis of the National Cooperative Growth Study Database. Pediatrics 1999;104:1028-1031
7. Ranke MB, Lindberg A, Price PA, Darendeliler F, Albertsson-Wikland K, Wilton P, Reiter EO. Age of growth hormone therapy at start and first-year responsiveness to growth hormone are major determinants of height outcomes in idiopathic short stature. Horm Res 2007;68:53-62
8. Wit JM, Rekers-Mombarg LTM. Final height gain by GH therapy in children with idiopathic short stature is dose dependent. J Clin Endocrinol Metab 2002;87:604-611